Novo Nordisk

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

US-listed shares of Novo jumped 8 per cent and Lilly fell 1 per cent in extended trading after the approval announcement

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

With Mounjaro gaining ground, launch comes just three months before Novo loses patent for semaglutide

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying Novo Nordisk's patent challenge needs a full hearing before any decision

The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk holds no patent, but barred sales in India until March 2026

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid subscriber base

Novo Nordisk will strengthen its oral semaglutide portfolio led by Rybelsus while cutting Wegovy injection prices by up to 37% to improve accessibility and expand its market in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

Novo Nordisk will cut 11.5 per cent of its workforce to save costs and streamline operations as competition rises and sales of Wegovy and Ozempic slow, especially in the US market

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

Microsoft, which has its largest quantum lab in Denmark, will provide software and Atom Computing will build the quantum computer